The estimated Net Worth of Arthur F Ryan is at least $32.2 Milión dollars as of 3 September 2024. Mr. Ryan owns over 100 units of Regeneron Pharmaceuticals stock worth over $20,183,119 and over the last 21 years he sold REGN stock worth over $11,314,284. In addition, he makes $724,993 as Independent Director at Regeneron Pharmaceuticals.
Arthur has made over 62 trades of the Regeneron Pharmaceuticals stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 100 units of REGN stock worth $117,869 on 3 September 2024.
The largest trade he's ever made was exercising 115,000 units of Regeneron Pharmaceuticals stock on 14 September 2011 worth over $2,084,950. On average, Arthur trades about 3,748 units every 56 days since 2004. As of 3 September 2024 he still owns at least 17,682 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Mr. Ryan stock trades at the bottom of the page.
Arthur F. Ryan serves as Independent Director of the Company. In 2008, Mr. Ryan retired as the Chairman of the Board of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. He served as Chief Executive Officer of Prudential until 2007. Prior to joining Prudential in 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990. Mr. Ryan managed Chase’s worldwide retail bank between 1984 and 1990. From 2008 to 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc. From 2009 to 2019, Mr. Ryan served as a director of Citizens Financial Group, Inc., a retail bank holding company that became publicly traded in 2014, and also served as its lead director, chair of the Compensation and Human Resources Committee, and a member of the Nominating and Corporate Governance Committee. Mr. Ryan’s substantial leadership experience as a chief executive officer of leading companies in the banking and insurance industries, and his extensive business experience and financial expertise, led the board to conclude that Mr. Ryan should serve as a director.
As the Independent Director of Regeneron Pharmaceuticals, the total compensation of Arthur Ryan at Regeneron Pharmaceuticals is $724,993. There are 15 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
Arthur Ryan is 77, he's been the Independent Director of Regeneron Pharmaceuticals since 2003. There are 1 older and 23 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis a Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: